Oculis Holding AG Announces Annual General Meeting Invitation
Based in Switzerland, Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) is set to conduct its Annual General Meeting for 2025, inviting all shareholders to participate. This significant event will take place on June 4, 2025, and will provide an excellent opportunity for shareholders to engage with the company's leadership.
Meeting Format and Access Details
Shareholders will have the chance to attend the meeting in person, and there will also be a live broadcast available. Those interested in participating can easily access the event through a special link that will be provided. Interested parties should ensure they save the date for this important gathering.
Virtual Information Session
In addition to the Annual General Meeting, Oculis will host a virtual information session on May 19, 2025, from 4:00 to 5:00 p.m. CEST. This session will allow shareholders to receive updates on meeting proposals and engage in Q&A with management. This proactive approach demonstrates Oculis’s commitment to maintaining open lines of communication with its investors.
Replays and Further Information
For those unable to join the live broadcast, a replay of the virtual information session will be made available on the Oculis website shortly after the event. Links to all relevant materials, including the recorded session and meeting resources, will also be accessible on their site, ensuring that shareholders have all the information they need.
About Oculis and Its Innovative Pipeline
Oculis is recognized as a leading global biopharmaceutical company dedicated to addressing unmet medical needs in the ophthalmic and neuro-ophthalmic fields. With a promising pipeline of clinically advanced product candidates, Oculis focuses on treatments that provide new hope for patients with conditions such as diabetic macular edema and dry eye disease.
Featured Products in Development
Among the standout products under development at Oculis are OCS-01, a topical eye drop aimed at diabetic macular edema, and Licaminlimab (OCS-02), designed to tackle dry eye disease. These innovative solutions reflect Oculis’s commitment to improving patient outcomes and advancing healthcare.
Connecting with Oculis
To learn more about the company's exciting projects and initiatives, stakeholders are encouraged to explore the Oculis website for the latest updates and information. The website serves as a vital resource for shareholders looking to stay informed about the company’s progress and innovations. Oculis’s experienced management team is determined to lead the company towards future success and expansion.
Frequently Asked Questions
What is the date of the Oculis Annual General Meeting?
The Oculis Annual General Meeting is scheduled for June 4, 2025.
Will the Annual General Meeting be accessible online?
Yes, there will be a live broadcast available for the Annual General Meeting.
When will the virtual information session take place?
The virtual information session will be held on May 19, 2025, from 4:00 to 5:00 p.m. CEST.
How can shareholders access the information session replay?
The replay of the virtual information session will be accessible on the Oculis website after the event.
What types of products is Oculis developing?
Oculis is developing innovative products such as OCS-01 for diabetic macular edema and Licaminlimab (OCS-02) for dry eye disease.
